Children With Diabetic Ketoacidosis at High Risk of AKI
Of the children who developed acute kidney injury, 34.9% had stage 1, 45.3% had stage 2, and 19.8% had stage 3.
Of the children who developed acute kidney injury, 34.9% had stage 1, 45.3% had stage 2, and 19.8% had stage 3.
There was also a 22% reduction in the development of renal outcomes with liraglutide compared to placebo.
Evacetrapib did lower low-density lipoprotein cholesterol in high vascular risk patients, but did not reduce major cardiovascular events.
CARIN trial reported no significant differences in acute kidney injury incidence between novel compound CMX-2043 and placebo.